Strategic Framework: China-to-Global Out-Licensing Surge
Macro drivers, deal structures, and cross-border commercial motivations
High-throughput modalities: Next-Gen ADCs (HER2, TROP2, B7-H4), PD-1/VEGF Bispecifics, Oral Small-Molecule Incretins, and In Vivo Cell Therapies.
Rapid replenishment of clinical pipelines ahead of the $230.0B USD Patent Cliff. Access to fast IND-to-trial execution (~60 days) and cost-effective clinical patient recruitment in China.
Domestic NRDL price cuts (50–70%) constrain local gross margins. Licensing out unlocks non-dilutive upfront cash (average $170M+ USD) to fund ongoing discovery R&D.
Shifting from single-asset ex-China rights to Multi-Target Platform Deals (e.g., AstraZeneca/CSPC $18.5B USD) and offshore NewCo structures in tax-neutral jurisdictions.
China-origin assets have moved from the periphery to the centre of global pharma deal-making. Between 2021 and 2025, announced China out-licensing deal value rose roughly tenfold as multinationals raced to refill pipelines ahead of a ~$230B USD patent cliff, while Chinese biotechs sought non-dilutive capital under domestic pricing pressure. This platform tracks the Top 50 out-licensing deals to give investors, BD teams, and policy observers a single comparable view: who is buying, which modalities command premiums, and how deal structures are evolving.
Deal data is compiled from public disclosures: company press releases and investor presentations, SEC / HKEX / SSE filings, NMPA and CDE registration records, and reputable industry media (e.g., Fierce Biotech, Endpoints News, BioCentury, PharmaDJ). Deal values represent total potential consideration as announced (upfront plus milestone payments), in nominal USD. Ranking is by total announced deal value; figures marked ~ are approximations.
This page is an independent research compilation for general information only. Data is drawn from sources believed reliable but is not independently audited; figures may be revised, restated, or differ from other compilations, and announced deal values may include contingent milestones that are never paid. Nothing here constitutes investment, legal, regulatory, or medical advice. Verify all figures against primary sources before relying on them.